Building partnerships to improve resilience and safety of ...
R&D Pharmaceutical Companies Partnerships to Improve Developing World Health
16
© IFPMA 2011 R&D Pharmaceutical Companies Partnerships to Improve Developing World Health Mario Ottiglio Associate Director, Public Affairs & Global Health Policy ICIUM 2011, Antalya, Turkey, 15 November 2011
-
Upload
maryam-sampson -
Category
Documents
-
view
21 -
download
0
description
R&D Pharmaceutical Companies Partnerships to Improve Developing World Health. Mario Ottiglio Associate Director, Public Affairs & Global Health Policy ICIUM 2011, Antalya, Turkey, 15 November 2011. Outline. Industry’s efforts in R&D for diseases of the developing world (DDW) - PowerPoint PPT Presentation
Transcript of R&D Pharmaceutical Companies Partnerships to Improve Developing World Health
© IFPMA 2011
R&D Pharmaceutical Companies Partnerships to ImproveDeveloping World Health
Mario OttiglioAssociate Director, Public Affairs & Global Health Policy
ICIUM 2011, Antalya, Turkey, 15 November 2011
© IFPMA 20112
1. Industry’s efforts in R&D for diseases of the developing world (DDW)
2. Industry’s access programmes
3. Focus: Challenges in R&D
4. Conclusive remarks
Outline
© IFPMA 2011
Tackling DDW
Basic Research
- Academia
- Government Agencies
- R&D Industry
Research & Development
- R&D Industry
- Product Development Partnerships (PDP)
Manufacture
- R&D Industry
- Generic Industry
Access and Delivery
- Governments
- Foundations
a combined effort to benefit patients in developing countries
© IFPMA 2011
Overall Industry Efforts in R&D for DDW
(Current industry involvement & partnerships - illustrative only - not comprehensive)
Industry Dedicated
DDW R&D Centers
Independent Efforts Partnerships
© IFPMA 2011
Industry DDW R&D
5
2005 2006 2007 2008 2009 2010 20110
10
20
30
40
50
60
70
80
90
100
DDW R&D, 2005-2011
Medicine R&D Projects Vaccine R&D Projects
R&D for TDR 10 Priority Diseases:
Chagas
Dengue
Human African Trypanosomiasis
Leishmaniasis
Leprosy
Lymphatic Filariasis
Malaria
Onchocerciasis
Schistosomiasis
Tuberculosis
*1 project = 1 compound in development or 1 screening program for 1 disease
© IFPMA 2011
DDW R&D is increasingly collaborative
2005
2006
2007
2008
2009
2010
2011
5 15 25 35 45 55 65 75
2005 2006 2007 2008 2009 2010 2011
Internal Projects 16 19 22 18 18 20 17
PDPs 16 30 37 49 66 71 76
R&D DDW Projects: Internal and PDPs
© IFPMA 2011
Industry R&D for DDW is Growing
© IFPMA 2011
Technology Transfer Happens
51 Case studies in the IFPMA booklet
23 IFPMA Member Companies are technology providers
> 40 Recipient countries with (China, India, SA, Thailand the best
represented)
7 Type of involved organizations: Donors, PPPs, IGOs,
Governments, PDPs, Universities, Private Companies
1985 year of the first programme of the booklet. Since 2000 the No.
has increased dramatically. Booklet includes programmes
active in last 5 years
Distribution of Tech Transfer programs
BRIC + MexAfricaOther
© IFPMA 2011
Industry Access Partnerships
9
© IFPMA 2011
Program Types
10
Access (32 % of all programs) Access (32 % of all programs)
Capacity Building (57 % of all programs) Capacity Building (57 % of all programs)
Education (30 % of all programs) Education (30 % of all programs)
R & D (25 % of all programs) R & D (25 % of all programs)
© IFPMA 2011
Programs by Disease Area
11
2006
2007
2008
2009
2010
0 10 20 30 40 50 60 70
Other InitiativesNCDsC & MPreventableTropicalMalariaTBHIV/AIDS
© IFPMA 2011
Largest Beneficiary in Each Region
12
Latin AmericaBrazil21 programs Sub-Saharan Africa
Kenya
49 programs
South AsiaIndia45 programs
Asia-Pacific
China
23 programs
EuropeUkraine11 programs
MediterraneanEgypt11 programs
© IFPMA 2011
Things Have Changed...
Product Development Partnerships
Large Scale Donor Funding
for Access
Increased not-for-profit R&D
work
New Approaches
© IFPMA 2011
…But Challenges Remain
•More projects entering expensive later stages (clinical trials)
•Need to invest in trials infrastructure & regulatory frameworks
•Regulatory delays can be significant (e.g. ~4 years in S. Africa)
Maturing Pipeline
•From Development, return to Basic Research (e.g. Dengue)
•Implications for total funding and for overall timeframe
Some Avenues of Research
Prove Fruitless
•Advanced Market Commitment (AMC)
•Priority Review Voucher (PRV)
•Recognition of Importance of DDW R&D
New Funding Sources / Incentives
© IFPMA 2011
Messages to take home
Industry’s role and unique speciality is in innovation: researching and developing drugs
As part of the solution, industry is also committed to increased access to healthcare and to maintain good corporate governance
Market failures are a reality: new complementary approaches such as Partnership are needed
Industry is ready to be engaged in constructive and inclusive dialogues
Access partnerships & drug donation programmes have raised the profile of the diseases, kick-started national diseases control programmes and improved delivery systems
The complexity of the issues is beyond the capability of any single organization or country alone
© IFPMA 2011
Thank You!
Ch. Louis-Dunant 15P.O. Box 195121211 Geneva 20Switzerland
Tel: +41-22-338 32 00Fax: +41-22-338 32 99Email: [email protected]: www.ifpma.org
